Develops and manufactures the trophon ultrasound probe disinfector. Provides consumables and accessories for the trophon device. Now — the numbers.
This is an established company with proven profits.
Average growth of 14% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $94.6M would still be left in the vault — a solid cushion for hard times.
The market pays 45.2× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 14% a year on average.
There is $111.2M in the vault; even if every debt were paid off, $94.6M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The company’s market value is 45 times its annual profit. Even a small disappointment could hit the price hard.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.